Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement

Kenneth J. Mandell; David Clark; David S. Chu; C. Stephen Foster; John Sheppard; Todd C. Brady

doi:10.1089/jop.2020.0056

Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement

Journal of Ocular Pharmacology and Therapeutics ◽

10.1089/jop.2020.0056 ◽

2020 ◽

Vol 36 (10) ◽

pp. 732-739

Author(s):

Kenneth J. Mandell ◽

David Clark ◽

David S. Chu ◽

C. Stephen Foster ◽

John Sheppard ◽

...

Keyword(s):

Anterior Uveitis ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

Reactive Aldehyde

Download Full-text

A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma

Acta Oncologica ◽

10.1080/0284186x.2021.1928281 ◽

2021 ◽

pp. 1-6

Author(s):

Peter C. Petersen ◽

Lone N. Petersen ◽

Ivan Vogelius ◽

Jon K. Bjerregaard ◽

Lene Baeksgaard

Keyword(s):

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

Esophagogastric Adenocarcinoma

Download Full-text

Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

Oral Oncology ◽

10.1016/j.oraloncology.2021.105192 ◽

2021 ◽

Vol 115 ◽

pp. 105192

Author(s):

Douglas R. Adkins ◽

Jin-Ching Lin ◽

Assuntina Sacco ◽

Jessica Ley ◽

Peter Oppelt ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Human Papillomavirus ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

P76.24 A Randomized Phase 2 Trial of Anlotinib Plus Docetaxel vs Docetaxel as 2nd-Line Therapy for EGFR-Negative NSCLC (ALTER-L018)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.01.1081 ◽

2021 ◽

Vol 16 (3) ◽

pp. S596

Author(s):

L. Wu ◽

Z. Wu ◽

Z. Xiao ◽

J. Weng ◽

M. Xiao ◽

...

Keyword(s):

Phase 2 ◽

Phase 2 Trial ◽

Line Therapy ◽

Randomized Phase 2

Download Full-text

Seven Days Treatment With the Angiotensin II Type 2 Receptor Agonist C21 in Hospitalized COVID-19 Patients: A Placebo-Controlled Randomized Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3889369 ◽

2021 ◽

Author(s):

Göran Tornling ◽

Rohit Batta ◽

Joanna C. Porter ◽

Bryan Williams ◽

Thomas Bengtsson ◽

...

Keyword(s):

Angiotensin Ii ◽

Receptor Agonist ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Durvalumab, Tremelimumab Alone or in Combination With Low-Dose or Hypofractionated Targeted Radiotherapy in Metastatic Non-Small Cell Lung Cancer Refractory to Prior PD-1 Therapy: A Multicentre, Open-Label, Randomized, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3922682 ◽

2021 ◽

Author(s):

Jonathan D. Schoenfeld ◽

Anita Giobbie-Hurder ◽

Srinika Ranasinghe ◽

Katrina Z. Kao ◽

Ana Lako ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Low Dose ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Targeted Radiotherapy ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Abstract PD1-06: Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2 trial

10.1158/1538-7445.sabcs20-pd1-06 ◽

2021 ◽

Author(s):

Joyce O'Shaughnessy ◽

Gail S Wright ◽

Anu R Thummala ◽

Michael A Danso ◽

Lazar Popovic ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Final Analysis ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

A Multi-Institutional Randomized Phase 2 Trial of the Oncolytic Virus Reolysin in the First Line Treatment Metastatic Adenocarcinoma of the Pancreas (Map)

Annals of Oncology ◽

10.1093/annonc/mdu438.19 ◽

2014 ◽

Vol 25 ◽

pp. v1 ◽

Cited By ~ 5

Author(s):

T. Bekaii-Saab ◽

A.M. Noonan ◽

G. Lesinski ◽

S. Mikhail ◽

K. Ciombor ◽

...

Keyword(s):

Oncolytic Virus ◽

Line Treatment ◽

Metastatic Adenocarcinoma ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Adenocarcinoma Of The Pancreas ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Updated Results From a Phase 1/Randomized Phase 2 Trial of Response-Adapted Volume De-escalation (RAVD) for Locally Advanced Head and Neck Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2016.06.544 ◽

2016 ◽

Vol 96 (2) ◽

pp. S219

Author(s):

J.M. Melotek ◽

V.M. Villaflor ◽

T.G. Karrison ◽

R.J. Brisson ◽

E.A. Blair ◽

...

Keyword(s):

Head And Neck Cancer ◽

Head And Neck ◽

Neck Cancer ◽

Phase 1 ◽

Locally Advanced ◽

Advanced Head ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis

American Journal of Clinical Nutrition ◽

10.1093/ajcn/84.6.1463 ◽

2006 ◽

Vol 84 (6) ◽

pp. 1463-1472 ◽

Cited By ~ 117

Author(s):

Samuele M Marcora ◽

Kathryn R Chester ◽

Gayatri Mittal ◽

Andrew B Lemmey ◽

Peter J Maddison

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Early Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase 2 ◽

Phase 2 Trial ◽

Factor Therapy ◽

Necrosis Factor ◽

Randomized Phase 2

Download Full-text

Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)

Targeted Oncology ◽

10.1007/s11523-020-00750-w ◽

2020 ◽

Vol 15 (5) ◽

pp. 623-633

Author(s):

Naoki Izawa ◽

Kohei Shitara ◽

Kimio Yonesaka ◽

Takeharu Yamanaka ◽

Takayuki Yoshino ◽

...

Keyword(s):

Tumor Shrinkage ◽

Line Treatment ◽

Second Line ◽

Phase 2 ◽

Wild Type ◽

Phase 2 Trial ◽

Depth Of Response ◽

Early Tumor Shrinkage ◽

Early Tumor ◽

Randomized Phase 2

Download Full-text